News | June 24, 2024
Ascentage Pharma closes US$ 75 million equity investment by Takeda
Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO
Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
These abstracts report on the company's three lead drug candidates, including olverembatinib
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
Almost 300 million people globally have chronic hepatitis B
Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)
Malaria is a life-threatening parasitic infection that is spread by the bites of mosquitoes carrying the Plasmodium parasite
The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications
Subscribe To Our Newsletter & Stay Updated
